Skip to main content

Table 1 SBP, DBP and PP during the study period by treatment group, repeated measures and Bonferroni post hoc analysis, using last observation carried forward method for missing data

From: Does Pomegranate intake attenuate cardiovascular risk factors in hemodialysis patients?

  

PJ

Placebo

P*****for PJ vs. placebo at zero time and at 12 m

 

Time

N

Mean ± SE (mm Hg)

P for trend

N

Mean ± SE (mm Hg)

P for trend

SBP

0

44

145.6 ± 21.9

0.001

21

129.6 ± 27.2

0.15

0.28

3 M

143.6 ± 23.9

131.2 ± 25.5

 

6 M

141.7 ± 20.4

138.8 ± 24.8

12 M

135.7 ± 21.3*

135.6 ± 27.7

0.96

SBP ≥ 140 at study initiation

0

26

157.8 ± 12.9

<0.001

5

162.0 ± 10.6

0.42

0.54

3 M

153.2 ± 18.8

157.1 ± 13.9

 

6 M

149.5 ± 14.8**

156.2 ± 17.6

12 M

144.0 ± 16.9*

157.8 ± 10.3

0.12

DBP††

0

44

70.9 ± 11.4

0.09

21

62.0 ± 15.7

0.46

0.09

3 M

70.6 ± 12.3

64.5 ± 13.5

 

6 M

69.6 ± 12.5

61.5 ± 16.5

12 M

67.7 ± 13.8

63.8 ± 20.4

0.38

PP†††

0

44

74.6 ± 19.5

0.04

21

64.3 ± 16.1

0.02

0.24

3 M

72.9 ± 20.0

66.5 ± 19.2

 

6 M

72.1 ± 17.0

77.3 ± 14.5****

12 M

68.0 ± 16.6***

68.8 ± 14.2

0.84

  1. *P < 0.05 for 12 m vs. 0 m and 3 m; **P < 0.05 for 6 m vs. zero time; ***P < 0.05 for 12 m vs. zero time; ****P < 0.05 for 6 m vs. zero time; *****T-test or Mann-whitny U test; †Systolic blood pressure; ††Diastolic blood pressure; ††† Pulse pressure.